Edwards Lifesciences Raises 2016 View
Disciplined Growth Investors’ managers have built a moderate allocation strategy unlike most others.
Declining fuel prices stoked great returns at several of these companies, but that's not a lasting advantage.
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
Ownership data provide a look at who else owns the company.
The information and opinions presented herein are not meant to be taken as investment advice. We do our best to make sure the information presented in this article is factual and correct, but Zacks cannot be held responsible for any losses incurred from investment transactions made based on ...